Powerful Efficacy with robust Cardio-Renal-Metabolic evidence Renal safety Renal evidence with Empagliflozin and Linagliptin1,2 Zoom Zoom Renal benefits with EMPA and LINA1,2 Glyxambi® is not indicated in the treatment of CKD. * Exploratory endpoint in the EMPA-REG OUTCOME® trial. # Prespecified microvascular endpoint in the CARMELINA® trial. † Exploratory outcome in the CARMELINA® trial. FDC: Fixed-dose combination. EMPA: Empagliflozin. LINA: Linagliptin. HR: Hazard ratio. RRR: Relative risk reduction. UACR: Urine albumin-to-creatinine ratio. Cl: Confidence interval. CKD: Chronic kidney disease. References: Wanner C, et al. N Engl J Med. 2016;375:323-334. Rosenstock J, et al. JAMA. 2019;321(1):6 9-79. Why Glyxambi®? Why Glyxambi®? Guidelines Efficacy Pleiotropic benefits Cardiovascular evidence Renal evidence Other safety Differentiation v/s other FDC Efficacy vs. Glimepiride Other benefits vs. Glimepiride